What is the appropriate evaluation and management of restless legs syndrome in an elderly patient?

Management of Restless Legs Syndrome in Elderly Patients

Start with gabapentin, pregabalin, or gabapentin enacarbil as first-line therapy in elderly patients with RLS, and avoid dopamine agonists as standard treatment due to augmentation risk. 1

Initial Evaluation

Diagnostic Criteria

Confirm RLS diagnosis by establishing all four essential features:

• Urge to move legs with uncomfortable sensations
• Symptoms begin or worsen during rest/inactivity
• Relief with movement (walking, stretching)
• Symptoms worse in evening/night 2

Special Considerations for Cognitively Impaired Elderly

Look for behavioral indicators rather than relying on patient report 2:

• Observable signs: Rubbing/kneading legs, groaning while holding extremities
• Motor activity: Pacing, fidgeting, repetitive kicking, foot tapping, cycling movements
• Timing patterns: These behaviors occur exclusively or worsen in evening/night and during inactivity

Essential Laboratory Testing

Check serum ferritin and transferrin saturation in all patients - this is critical as iron deficiency is a treatable secondary cause 2. The guidelines reference "appropriate iron status" for iron therapy decisions, though specific thresholds are mentioned for ESRD patients (ferritin <200 ng/mL, transferrin saturation <20%) 1.

Neurologic Examination

Perform thorough neurologic exam to exclude secondary causes: peripheral neuropathy, radiculopathy, vascular disease, arthritis 2.

Treatment Algorithm

First-Line Pharmacologic Therapy (Strong Recommendations)

The 2025 AASM guidelines provide strong recommendations for three agents 1:

1. Gabapentin enacarbil (preferred formulation)
2. Gabapentin
3. Pregabalin

These α2δ calcium channel ligands are now the mainstay of treatment, representing a major shift from previous dopamine-focused approaches 3.

Iron Supplementation Based on Iron Status

If iron deficiency present:

• IV ferric carboxymaltose receives a strong recommendation with moderate certainty evidence 1
• Oral ferrous sulfate is a conditional recommendation 1
• Other IV formulations (low molecular weight iron dextran, ferumoxytol) have conditional recommendations 1

Critical caveat: Ferric carboxymaltose carries higher risk of hypophosphatemia compared to other IV iron formulations 3.

Second-Line Options (Conditional Recommendations)

If first-line agents fail or are contraindicated:

• Extended-release oxycodone and other opioids - conditional recommendation with moderate certainty evidence 1. Recent data from the National RLS Opioid Registry show reassuring safety findings 3
• Dipyridamole - conditional recommendation 1
• Bilateral high-frequency peroneal nerve stimulation - conditional recommendation, can serve as adjunct therapy in refractory cases 1, 3

Medications to AVOID in Elderly Patients

Strong recommendation AGAINST:

• Cabergoline - do not use 1

Conditional recommendations AGAINST standard use:

• All dopamine agonists (pramipexole, ropinirole, rotigotine) - the 2025 guidelines downgraded these due to augmentation risk 1, 3
  • May consider for short-term use only if patient prioritizes immediate symptom relief over long-term augmentation risk
• Levodopa - particularly problematic for augmentation 1
• Benzodiazepines (clonazepam) - especially concerning in elderly due to fall risk 1
• Anticonvulsants (carbamazepine, valproic acid) 1
• Bupropion 1

Critical Pitfalls in Elderly Patients

Augmentation with Dopaminergic Therapy

This is the primary reason dopamine agonists were downgraded in 2025 guidelines 3. Augmentation means:

• Earlier onset of symptoms during the day
• Shorter latency to symptoms at rest
• Spread to other body parts
• Increased symptom intensity

In elderly patients with prolonged medication use, augmentation becomes particularly problematic and difficult to manage 4.

Drug Interactions and Metabolism

Elderly patients have:

• Slower drug metabolism requiring dose adjustments
• Higher risk of orthostatic hypotension (particularly with dopamine agonists if used)
• Increased sedation risk
• Multiple concurrent medications requiring interaction screening 5, 6

Special Population: RLS with End-Stage Renal Disease

If patient has ESRD 1:

• Gabapentin - conditional recommendation
• IV iron sucrose if ferritin <200 ng/mL and transferrin saturation <20%
• Vitamin C - conditional recommendation
• Avoid standard dopaminergic therapy

Practical Implementation

Start conservatively in elderly patients:

• Begin with one of the three strongly recommended α2δ ligands
• Titrate slowly given age-related pharmacokinetic changes
• Address iron deficiency if present before or concurrent with other therapy
• Monitor for side effects: dizziness, somnolence, peripheral edema
• If inadequate response, consider adding opioid therapy rather than switching to dopamine agonists
• Reserve dopamine agonists only for short-term use in carefully selected patients who understand augmentation risks

The paradigm shift in the 2025 guidelines away from dopamine agonists as first-line therapy is particularly important for elderly patients, who face greater challenges managing augmentation and medication side effects over the long term 3, 7.